Soon S. Kim

Suwon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 141 publications

Toward a future role for liver biopsy in HCC: literature evidence and survey-based perspectives from Korean experts.

Toward a future role for liver biopsy in HCC: literature evidence and survey-based perspectives from Korean experts.

Journal: Journal of liver cancer
Published: May 04, 2026

Comprehensive Multi-Omics Characterization of CYP2R1 as a Diagnostic and Functional Biomarker in Hepatocellular Carcinoma.

Comprehensive Multi-Omics Characterization of CYP2R1 as a Diagnostic and Functional Biomarker in Hepatocellular Carcinoma.

Journal: Medical sciences (Basel, Switzerland)
Published: February 19, 2026

Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation.

Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation.

Journal: Molecular oncology
Published: February 10, 2026

Systematic transcriptomic analysis of UDP-glucuronosyltransferases reveals UGT2B11 as a diagnostic and metabolic marker in hepatocellular carcinoma.

Systematic transcriptomic analysis of UDP-glucuronosyltransferases reveals UGT2B11 as a diagnostic and metabolic marker in hepatocellular carcinoma.

Journal: BMC cancer
Published: February 05, 2026

Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Journal: Gut and liver
Published: January 10, 2026

Plasma interleukin-8 as a predictive biomarker for tyrosine kinase inhibitor response in advanced hepatocellular carcinoma.

Plasma interleukin-8 as a predictive biomarker for tyrosine kinase inhibitor response in advanced hepatocellular carcinoma.

Journal: Discover oncology
Published: January 09, 2026

Correspondence to editorial on "Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host-microbe signaling and highlights 2-hydroxyisocaproate as a potential effector".

Correspondence to editorial on "Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host-microbe signaling and highlights 2-hydroxyisocaproate as a potential effector".

Journal: Clinical and molecular hepatology
Published: December 13, 2025

Metabolic Dysfunction-Associated Steatotic Liver Disease and Vascular Complications: Associations with Serum Testosterone Levels in a Korean Multicenter Male Cohort.

Metabolic Dysfunction-Associated Steatotic Liver Disease and Vascular Complications: Associations with Serum Testosterone Levels in a Korean Multicenter Male Cohort.

Journal: Gut and liver
Published: November 27, 2025

DKK1 Suppresses Hippo Signaling via PIP3-OGT-LRP6 O-GlcNAcylation in Hepatocellular Carcinoma.

DKK1 Suppresses Hippo Signaling via PIP3-OGT-LRP6 O-GlcNAcylation in Hepatocellular Carcinoma.

Journal: Cancer communications (London, England)
Published: November 12, 2025

GAFAD: A liquid chromatography-tandem mass spectrometry-based model for early hepatocellular carcinoma detection beyond GALAD's limitations.

GAFAD: A liquid chromatography-tandem mass spectrometry-based model for early hepatocellular carcinoma detection beyond GALAD's limitations.

Journal: Clinical and molecular hepatology
Published: October 31, 2025

Enhanced pathogen detection and gut microbiome alterations in pyogenic liver abscess: insights from next-generation sequencing.

Enhanced pathogen detection and gut microbiome alterations in pyogenic liver abscess: insights from next-generation sequencing.

Journal: Gut pathogens
Published: October 12, 2025

Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection.

Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection.

Journal: World journal of gastroenterology
Published: September 17, 2025
Showing 1-12 of 141

Last Updated: 09/26/2026